[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336439-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336439-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","similar-genetic-profile-in-early-and-late-stage-urothelial-tract-cancer-research-findings-for-genomic-and-transcriptomic-landscape","Similar genetic profile in early and late stage urothelial tract cancer - Research findings for genomic and transcriptomic landscape","","Urothelial tract cancer is a major cancer burden worldwide, yet advanced patients with limited treatment options still face uncertainty about the mutational landscape. This study compares genomic and transcriptomic profiles and potential targeted treatment options between metastatic urothelial tract cancer patients receiving multiple therapy lines and newly diagnosed, untreated muscle-invasive bladder cancer patients. It uses two cohorts (CoPPO and TCGA BLCA) with 523 cancer genes assessed by targeted sequencing, including RNA-based molecular subtype prediction.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/similar-genetic-profile-in-early-and-late-stage-urothelial-tract-cancer-research-findings-for-genomic-and-transcriptomic-landscape/336439/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/similar-genetic-profile-in-early-and-late-stage-urothelial-tract-cancer-research-findings-for-genomic-and-transcriptomic-landscape/336439.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient groups were compared in this study?","Question",{"text":63,"@type":64},"Metastatic urothelial tract cancer patients treated with multiple therapy lines (CoPPO cohort) were compared with newly diagnosed, untreated muscle-invasive bladder cancer patients using TCGA BLCA data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were genomic alterations assessed across cohorts?",{"text":68,"@type":64},"The study used a TrueSight Oncology-500 targeted sequencing panel covering 523 highly important cancer-related genes from both cohorts, combined with RNA count data to infer molecular subtypes.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about the mutational profile across stages?",{"text":72,"@type":64},"Focusing on 523 highly relevant cancer genes, the mutational profile of heavily treated metastatic urothelial tract cancer resembled that of newly diagnosed muscle-invasive bladder cancer, suggesting alterations that may be targetable.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336439,1790719027,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Journal of Cancer Research and Clinical Oncology (2024) 150:339  \n[https://doi.org/10.1007/s00432-024-05850-y](https://doi.org/10.1007/s00432-024-05850-y)  \nRESEARCH  \nSimilar genetic profile in early and late stage urothelial tract cancer  \nDag Rune Stormoen1,2 · Kristoffer Staal Rohrberg1,2 · Kent William Mouw3,4 · Katrine Ørum1 · Zoltan Szallasi4,5,6 · Maria Rossing2,7 · Frederik Otzen Bagger7 · Helle Pappot1,2  \nReceived: 13 May 2024 / Accepted: 14 June 2024 / Published online: 8 July 2024 © The Author(s) 2024  \nAbstract  \nIntroduction Urothelial tract cancer (UTC) ranks as the tenth most prevalent cancer and holds the seventh position in terms of mortality worldwide. Despite its prevalence and mortality ranking, there are still gaps in the knowledge of the mutational landscape in patients with advanced disease who have limited therapeutic options after multiple lines of prior treatment. This study compares the genomic and transcriptomic landscape, and targeted treatment options between metastatic UTC (mUTC) patients treated with multiple lines of therapy compared to newly diagnosed, untreated Muscle Invasive Bladder Cancer (MIBC) .  \nMethods We compared genomic and clinical data from two cohorts: mUTC patients who received multiple lines of therapy and were referred to the Copenhagen Prospective Personalized Oncology (CoPPO) project at Rigshospitalet, University of Copenhagen. Data for MIBC UTC patients were acquired from the Cancer Genome Atlas Bladder Cancer (TCGA BLCA) cohort. Biopsies in CoPPO were performed at the time of enrollment. 523 highly important cancer-related genes (TrueSight Oncology-500 targeted sequencing panel) were used from both cohorts for comparative analysis. Analyses included RNA count data to compare predicted molecular subtypes in each cohort separately.  \nResults Patients from the CoPPO cohort had a lower median age at first-line treatment than the TCGA BLCA cohort, with no significant gender disparity. The predominant histology was urothelial cell carcinoma in both cohorts. Genomic analysis revealed no significant difference between the top mutated genes in the two cohorts, specifically looking into DNA damage repair genes. Molecular subtyping indicated a higher frequency of neuroendocrine differentiation in the CoPPO cohort. 13% of patients in the CoPPO cohort received targeted therapy based on genomic findings, and 16% received non-targeted treatment, totaling 29% receiving CoPPO treatment (9 patients) . The remaining 71% received best supportive care. KaplanMeier analysis showed a non-significant survival benefit for the intervention group in the CoPPO cohort.  \nConclusion When focusing on 523 highly relevant cancer genes, the mutational profile of mUTC patients who have undergone numerous treatment lines resembles that of newly diagnosed MIBC. These alterations can be targeted, indicating the potential advantage of early genomic testing for personalized treatment within clinical trials.  \nKeywords Urothelial tract cancer · Genomic evolution · Targeted therapy · Molecular subtyping · Phase 1 trials  \n􀀍 Dag Rune Stormoen [dag.rune.stormoen@regionh.dk](dag.rune.stormoen@regionh.dk)  \n1 Department of Oncology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen 5073, Denmark  \n2 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark  \n3 Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA  \n4 Harvard Medical School, Boston, MA, USA  \n5 Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, USA  \n6 Translational Cancer Genomics Group, Danish Cancer Society, Copenhagen, Denmark  \n7 Department for Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark  \nIntroduction  \nUrothelial tract cancer (UTC) is the tenth most prevalent form of cancer worldwide and the thirteenth in terms of cancer-related mortality (Saginala et al. 2020; Sung et al. 2021) . In early-stage, localiz","cbCaimiPV1gR4azz","https://ap.wps.com/l/cbCaimiPV1gR4azz","pdf",4661763,13,"English","# Methods\n## Cohorts and data sources\n## Targeted sequencing and molecular subtyping\n# Results\n## Cohort demographics and histology\n## Genomic comparison and targeted treatment rates\n## Survival analysis\n# Conclusion\n## Clinical implications of early genomic testing","[{\"question\":\"What patient groups were compared in this study?\",\"answer\":\"Metastatic urothelial tract cancer patients treated with multiple therapy lines (CoPPO cohort) were compared with newly diagnosed, untreated muscle-invasive bladder cancer patients using TCGA BLCA data.\"},{\"question\":\"How were genomic alterations assessed across cohorts?\",\"answer\":\"The study used a TrueSight Oncology-500 targeted sequencing panel covering 523 highly important cancer-related genes from both cohorts, combined with RNA count data to infer molecular subtypes.\"},{\"question\":\"What did the study find about the mutational profile across stages?\",\"answer\":\"Focusing on 523 highly relevant cancer genes, the mutational profile of heavily treated metastatic urothelial tract cancer resembled that of newly diagnosed muscle-invasive bladder cancer, suggesting alterations that may be targetable.\"}]","Similar genetic profile in early and late stage urothelial tract cancer - Research findings for genomic and transcriptomic landscape | PDF",1790015064,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e4f02473a69f29feecd658e9080fff7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/492ce6476dfd964734484183bd5d37d9.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a13ab29dc2869bfef1b84131afea652.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f3448480e962b08b9565e53e72c6090.webp",980,1301]